SightfileU.S. market data from official filings

HALOZYME THERAPEUTICS INC (HALO)

Name: HALOZYME THERAPEUTICS INC (HALO) — Institutional ownership, SEC filings and insider activity
Creator: Sightfile
License: https://www.sec.gov/privacy#dissemination

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001159036 · EDGAR filings · Updated 2026-07-09

HALOZYME THERAPEUTICS INC (HALO) has reported institutional ownership of 101.3%, with 631 institutional managers holding positions valued at $7.77B per the latest 13F reporting period.

Institutional ownership

101.3%

Institutional managers

631

Reported 13F value

$7.77B

Insider activity

152 trans.

−$36.8M net selling

Latest updates

2026-07-09 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Insider transaction reported (Form 4)
2026-07-02 — Current report (8-K) filed
2026-06-30 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, HALOZYME THERAPEUTICS INC has 631 institutional holders and institutional ownership of 101.3%.

Insider activity

Insiders reported 152 transactions (0 buys, 80 sells) across 11 reporting insiders, with a net reported value of −$36.8M.

Related companies

SOLVENTUM CORP (SOLV) · PROTAGONIST THERAPEUTICS (PTGX) · KYMERA THERAPEUTICS (KYMR) · REPLIGEN CORP COM (RGEN) · ARROWHEAD PHARMACEUTICALS IN (ARWR) · KRYSTAL BIOTECH INC (KRYS)

See full history, cross-references and alerts on Sightfile

Sightfile provides information only — not investment advice, recommendations, or an assessment of any security. Data is derived from official public sources (SEC EDGAR and U.S. government agencies), may contain errors or delays, and should be verified against the source filing before relying on it.
Data sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-09.